Astrocytoma, IDH-mutant, grade 4
MONDO:0956981An IDH-mutant anaplastic astrocytoma that is characterized by the presence of necrosis and/or microvascular proliferation or homozygous deletion of CDKN2A and/or CDKN2B genes. The term glioblastoma no longer applies to central nervous system WHO grade 4 IDH-mutant astrocytomas.
2849 clinical trials for this condition and its sub-types, 22 tagged with Astrocytoma, IDH-mutant, grade 4 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for brain cancer? drug shows promise in early trial
Disease control OngoingThis study tests a drug called abemaciclib in people whose glioblastoma (a type of brain cancer) has come back. The drug is given before surgery to see how much reaches the tumor, and then to a separate group to see if it helps control the cancer for at least 6 months. The trial …
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Immunotherapy shows promise for tough brain cancers
Disease control OngoingThis study tests whether two immunotherapy drugs, ipilimumab and nivolumab, can shrink or slow the growth of recurrent high-grade gliomas (brain tumors) that have a high number of genetic mutations. About 37 adults with recurrent WHO grade 4 glioma will receive these drugs. The g…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a targeted antibody take on glioblastoma?
Disease control OngoingThis phase 1 trial is testing whether amivantamab, an antibody drug given by IV, is safe and tolerable for people with high-grade malignant brain tumors like glioblastoma. The study enrolls about 12 patients with recurrent glioblastoma or certain molecular subtypes. Participants …
Phase 1 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New radiation boost shows promise for elderly glioblastoma patients
Disease control OngoingThis phase 2 trial tests a higher radiation dose given over just 3 weeks for patients 65 and older with glioblastoma or grade 4 astrocytoma. Using a special MRI-guided machine (MR-Linac), doctors can adjust the radiation daily to target the tumor more precisely. The goal is to se…
Phase 2 • Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug targets genetic weakness in deadly brain tumor
Disease control OngoingThis clinical trial tests a new drug called vebreltinib (PLB1001) in people with a recurrent form of glioblastoma that has a specific genetic change (ZM fusion gene). The study compares vebreltinib to standard chemotherapy to see if it helps people live longer. About 84 participa…
Phase 2/3 • Sponsor: Beijing Pearl Biotechnology Limited Liability Company • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC